

Supplementary Figure 1



Supplemental Figure 1. Comparison of truth data with teacher-model inferences, and teacher-model inferences with student-model inferences. A) In a held-out set of 1,214 participants with truth data, the Pearson correlation between the previously-quantified liver fat ('True liver fat') and liver fat inferred from the ML teacher model was 0.974 (95% CI 0.971-0.977; P<2.4x10⁻⁷⁸⁴). B) In a separate held-out set of 390 samples with both gradient-echo and IDEAL imaging who were not used for model creation, the Pearson correlation between the teacher model inferred liver fat was 0.992 (95% CI 0.990-0.993; P = 3.1×10^{-351}). Blue points indicate European ancestries (whether the sample was included in the GWAS, as defined in the methods), gray points indicate all other ancestries.

Supplementary Figure 2



Supplemental Figure 2. Prediction of liver fat using a variable beta regression model of clinical and anthropometric measurements. In a held-out set of 1,196 participants of all ancestries with truth data, the Pearson correlation between the previously-quantified liver fat and liver fat estimated from clinical data was 0.453 (95% Cl 0.407-0.497; P=9.9x10⁻⁶²). Measurements that were at least nominally associated with liver fat in univariable analysis and therefore included in the beta regression model were: BMI, waist circumference, hip circumference, total body fat mass, total body fat percent, age at baseline, sex, height, weight, trunk fat mass, trunk fat percent, WHR, LDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), ALT/AST, gamma glutamyltransferase, hemoglobin A1c, random glucose, and C-reactive protein. Lipid measures were adjusted for lipid-lowering medication use and blood pressure was adjusted for anti-hypertensive medication use, as previously described ((Ehret et al., 2016; Patel et al., 2020).

Supplemental Table 1. Baseline characteristics of	participants in UK Biobank who underwent abdominal imaging.

	Overall
	(N=36,703)
Female	19049 (51.9%)
Age at enrollment, years	54.9 (7.47)
Age at imaging, years	64.2 (7.56)
Race	
White	35572 (96.9%)
Black	214 (0.6%)
South Asian	313 (0.9%)
Other Asian	165 (0.4%)
Multiple or other	336 (0.9%)
Coronary artery disease	1283 (3.5%)
Diabetes	1956 (5.3%)
Obese or severely obese	6495 (17.7%)
Hypertension	11085 (30.2%)
Excessive alcohol intake	2015 (5.5%)
Medications	
Blood pressure medications	4940 (13.5%)
Lipid-lowering therapy	5552 (15.1%)
Anthropometric data	
Weight, kg	76.8 (14.8)
Waist-to-hip ratio	0.859 (0.0871)
Body mass index, kg/m ²	26.6 (4.19)
Body fat, %	30.0 (8.17)
Systolic blood pressure	135 (17.6)
Weekly drinks, American standard	5.48 (6.37)
Liver-associated biomarkers	
Alanine aminotransferase (IU/L)	23.0 (13.9)
Aspartate aminotransferase (IU/L	25.8 (10.5)
Gamma glutamyltransferase (IU/L)	33.7 (33.9)
Lipid biomarkers	
Total cholesterol, mg/dl	221 (42.0)
LDL cholesterol, mg/dl	138 (32.1)
HDL cholesterol, mg/dL	57.0 (14.5)
Triglycerides, mg/dL	123 [88-179]
Glycemic biomarkers	
Glycated hemoglobin, %	5.36 (0.475)
Glucose, mg/dL	89.9 (17.5)
Liver fat at imaging, %	2.22 [1.57-4.17]

Values correspond to number (%), mean (standard deviation), or median [interquartile range].

Supplementary Table 2. Definitions of disease in each cohort.

Cohort	Disease	Definition
UK Biobank	NAFLD	Hospitalization due to nonalcoholic fatty liver (ICD10 K76.0) or other specified inflammatory liver diseases including nonalcoholic steatohepatitis (ICD10 K75.8)
UK Biobank	NASH	Hospitalization due to other specified inflammatory liver diseases including nonalcoholic steatohepatitis (ICD10 K75.8)
UK Biobank	NAFLD/NASH	Hospitalization due to nonalcoholic fatty liver (ICD10 K76.0) or other specified inflammatory liver diseases including nonalcoholic steatohepatitis (ICD10 K75.8)
UK Biobank	Cirrhosis	Hospitalization or death due to (ICD10; ICD9 codes): cirrhosis (K74.6; 5715), alcoholic cirrhosis or liver damage (K70.3; 5712, 5713), oesophageal varices (I85.0,I85.9; 4560, 4561) or portal hypertension (K76.6; 5723)
UK Biobank	Hepatocellular Carcinoma	Hospitalization due to liver cell carcinoma (ICD10 C22.0)
UK Biobank	Coronary Artery Disease	Self report of heart attack diagnosed by doctor (df-6150), self-reported myocardial infarction, coronary angioplasty or coronary artery bypass graft or triple heart bypass during verbal interview with trained nurse (df-20002, df-20004), hospitalization or death due to myocardial infarction (ICD10 I21, I21.0-4, I21.9, I22, I22.0, I22.1, I22.8, I22.9, I23, I23.06, I23.8; ICD9 410, 4109, 412, 4129), ischemic heart disease ICD10 (I24, I24.0, I24.1, I24.8, I24.9, I25.2; ICD9 411, 4119); operative procedures: replacement of coronary artery(ies)(K40, K40.14, K40.89, K41, K41.14, K41.89, K42,K42.14,K42.89, K43, K43.14, K43.89, K44, K44.14, K44.89), connection of thoracic artery to coronary artery (K45.1-K45.6, K45.89), other bypass of coronary artery(ies) (K46, K46.1-K46.6, K46.89) percutaneous transluminal balloon angioplasty of coronary artery(ies) (K49.14,K49.89), transluminal operations on coronary artery (K50.12, K50.4), percutaneous transluminal balloon angioplasty and insertion of stent into coronary artery (K75.14,K75.89)
UK Biobank	Diabetes	Self report of diabetes diagnosed by doctor (df-2443), self-reported diabetes during verbal interview with trained nurse (df-20002), started insulin within one year diagnosis of diabetes, self- reported insulin medication, hospitalization or death due to diabetes (ICD10 E10, E10.09, E11, E11.09, E12, E12.1, E12.8, E12.9, E13, E13.19, E14, E14.09; ICD9 2500, 25000, 25001, 25009, 2501, 25011, 25019, 2503, 2504, 2505, 25099)
UK Biobank	Hypertension	 Self-report of high blood pressure diagnosed by doctor (df-6150), self-reported hypertension, or essential hypertension during verbal interview with trained nurse (df-20002); hospitalization or death due to (ICD10; ICD9 codes) essential hypertension (I10; 401, 4010, 4011, 4019), hypertensive heart disease (I11, I11.0, I11.9, I13, I13.0-13.2; 402, 4020, 4021, 4029, 404, 4040, 4041, 4049), hypertensive renal disease (I12, I12.0, I12.9, I13, I13.0-13.2; 403, 4030, 4031, 4039, 404, 4040, 4041, 4049), secondary hypertension or renovascular hypertension (I15, I15.0-15.2, I15.8, I15.9; 405, 4050, 4051, 4059)
Mass General Brigham Biobank	NAFLD/NASH	Hospitalization due to nonalcoholic fatty liver (ICD10 K76.0) or nonalcoholic steatohepatitis (ICD10 K75.81)

Supplementary Table 3. Effects of variants previously associated with quantitative liver fat in common variant association study, and cirrhosis-associated variants nominated to affect liver fat, on liver fat in 32,976 individuals in UK Biobank.

rs780094 2 27741237 T C 0.38 0.04 3.50E-06 GCKR (Speliotes et al., 2011; Palmer et al., 2017; Palmer et al., 2018; Ma et al., 2010; Palmer et al., 2018; Palmer et al., 2010; Palmer et al., 2013; Palmer et al., 2013; Palmer et al., 2013; Palmer et al., 2013; Palmer			Position	Effect	Other	Effect Allele	Effect on liver fat			
rs780094 2 27741237 T C 0.38 0.04 3.50E-06 GCKR (Speliotes et al., 2011; Palmer et al., 2010; rs641738 19 54676763 C T 0.09 -0.02 0.10 PPP1R3B (Speliotes et al., 2011; Palmer et al., 2011; Palmer et al., 2010; Palmer et al., 201	Variant	Chr.	(hg19)	Allele	Allele	Freq.	(SD)	P value	Locus	Previous reference(s)
rs2228603 19 19329924 C T 0.92 -0.22 1.80E-51 NCAN (Speliotes et al., 2011; Palmer et al., 2011	rs1260326	2	27730940	Т	С	0.39	0.04	4.10E-07	GCKR	(Palmer et al., 2013; Parisinos et al., 2020)
rs12137855 1 219448378 C T 0.79 0.01 0.46 LYPLAL1 (Speliotes et al., 2011; Palmer et al., 2010; Palmer et al., 2013; Palmer et al., 2011; Palmer et al., 2013; Palmer et al., 2013; Palmer et al., 2013; Palmer et al., 2013;	rs780094	2	27741237	Т	С	0.38	0.04	3.50E-06	GCKR	(Speliotes et al., 2011; Palmer et al., 2013)
rs4240624 8 9184231 G A 0.09 -0.02 0.10 PPP1R3B (Speliotes et al., 2011; Palmer et al., 2015; Mancina et al., 2017; Palmer et al., 2019; Palmer et al., 2018; Ma et al., 2010; Palmer et al., 2018; Ma et al., 2020; Palmer et al., 2018; Ma et al., 2020; Palmer et al., 2018; Ma et al., 2010; Palmer et al., 2010	rs2228603	19	19329924	С	Т	0.92	-0.22	1.80E-51	NCAN	(Speliotes et al., 2011; Palmer et al., 2013)
rs641738 19 54676763 C T 0.56 -0.03 8.80E-06 MBOAT7-TMC4 (Buch et al., 2015; Mancina et al., 2017) rs62305723 4 88231429 G A 0.93 0.01 0.59 HSD17B13 (Ma et al., 2015; Mancina et al., 2017) rs6834314 4 88213808 A G 0.72 0.01 0.32 HSD17B13 Gellert-Kristensen et al., 2020) rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2020) rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2020) rs11597086 10 101953705 A C 0.55 0.02 0.01 CHUK (Feitosa et al., 2013)	rs12137855	1	219448378	С	Т	0.79	0.01	0.46	LYPLAL1	(Speliotes et al., 2011; Palmer et al., 2013)
rs62305723 4 88231429 G A 0.93 0.01 0.59 HSD17B13 (Ma et al., 2019) rs6834314 4 88213808 A G 0.72 0.01 0.32 HSD17B13 (Abul-Husn et al., 2018; Ma et al., 201 rs6834314 4 88213808 A G 0.72 0.01 0.32 HSD17B13 Gellert-Kristensen et al., 2020) rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2020) rs11597086 10 101953705 A C 0.55 0.02 0.01 CHUK (Feitosa et al., 2013)	rs4240624	8	9184231	G	А	0.09	-0.02	0.10	PPP1R3B	(Speliotes et al., 2011; Palmer et al., 2013)
rs6834314 4 88213808 A G 0.72 0.01 0.32 HSD17B13 (Abul-Husn et al., 2018; Ma et al., 2020) rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2018; Ma et al., 2010) rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2020) rs11597086 10 101953705 A C 0.55 0.02 0.01 CHUK (Feitosa et al., 2013)	rs641738	19	54676763	С	Т	0.56	-0.03	8.80E-06	MBOAT7-TMC4	(Buch et al., 2015; Mancina et al., 2016)
rs6834314 4 88213808 A G 0.72 0.01 0.32 HSD17B13 Gellert-Kristensen et al., 2020) rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2018; Ma et al., 201 rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2020) rs11597086 10 101953705 A C 0.55 0.02 0.01 CHUK (Feitosa et al., 2013)	rs62305723	4	88231429	G	Α	0.93	0.01	0.59	HSD17B13	(Ma et al., 2019)
rs72613567 4 88231392 T TA 0.73 0.01 0.40 HSD17B13 Gellert-Kristensen et al., 2020) rs11597086 10 101953705 A C 0.55 0.02 0.01 CHUK (Feitosa et al., 2013)	rs6834314	4	88213808	А	G	0.72	0.01	0.32	HSD17B13	(Abul-Husn et al., 2018; Ma et al., 2019; Gellert-Kristensen et al., 2020)
	rs72613567	4	88231392	Т	ТА	0.73	0.01	0.40	HSD17B13	(Abul-Husn et al., 2018; Ma et al., 2019; Gellert-Kristensen et al., 2020)
	rs11597086	10	101953705	А	С	0.55	0.02	0.01	CHUK	(Feitosa et al., 2013)
IS10883451 10 101924418 1 C 0.50 0.02 0.02 ERLINT (Peilosa et al., 2013)	rs10883451	10	101924418	Т	С	0.50	0.02	0.02	ERLIN1	(Feitosa et al., 2013)

Effects on inverse-normal transformed liver fat are given in units of standard deviation (SD).

							consumpt	isted for ion (origi n=32976	inal CVAS,	consu	d excess mers exe n=30197		Former alcohol consume excluded, adjusted for number of weekly drink (n=32043)		
Lead Variant	Chr.	Position (hg19)	Nearest Gene	Effect Allele	Other Allele	Effect Allele Freq.	Effect on liver fat (SD)	SE (SD)	P value	Effect on liver fat (SD)	SE (SD)	P value	Effect on liver fat (SD)	SE (SD)	P value
Newly-Identified Variants							-								
rs2642438	1	220970028	MARC1	G	А	0.70	0.052	0.008	1.70E-09	0.046	0.009	4.20E-07	0.050	0.009	8.70E-09
rs1229984	4	100239319	ADH1B	С	Т	0.98	0.158	0.025	7.00E-10	0.147	0.026	1.40E-08	0.153	0.026	3.40E-09
rs112875651	8	126506694	TRIB1	G	А	0.61	0.050	0.008	3.80E-10	0.052	0.008	3.50E-10	0.053	0.008	3.70E-11
rs2250802	10	113921354	GPAM	G	А	0.27	0.054	0.009	1.40E-09	0.056	0.009	2.10E-09	0.056	0.009	3.70E-10
rs56252442	19	18229208	MAST3	Т	G	0.25	0.049	0.009	2.70E-08	0.051	0.009	3.20E-08	0.050	0.009	1.70E-08
Previously-Reported Variants															
rs58542926	19	19379549	TM6SF2	Т	С	0.07	0.289	0.015	2.80E-85	0.283	0.015	1.60E-75	0.288	0.015	6.10E-83
rs429358	19	45411941	APOE	Т	С	0.85	0.121	0.011	1.50E-29	0.114	0.011	4.80E-24	0.120	0.011	3.90E-28
rs738408	22	44324730	PNPLA3	Т	С	0.21	0.195	0.009	5.30E-95	0.191	0.010	3.10E-84	0.194	0.010	1.10E-92

Supplementary Table 4. Effects of CVAS top variants after adjusting for alcohol consumption.

Excessive alcohol consumption was defined as >14 weekly drinks for women and >21 weekly drinkers for men. Chr., chromosome; Freq., frequency; SD, standard deviation; SE, standard error.

Supplementary Table 5. Replication of eight loci associated with liver fat in the discovery CVAS of liver fat in UK Biobank in two additional cohorts.

						UK	Biobank Dis	covery C	VAS		Framing	jham He	art Study I	Replicat	ion	MESA Replication				Combined Framingham + MESA Replication		
						Effect	Effect on					Effect	Effect on				Effect on			Effect on		
		Position	Nearest	Effect	Other	Allele	MRI liver	SE		Effect	Other	Allele	CT liver	SE		Effect	CT liver	SE		CT liver	SE	
Lead Variant	Chr.	(hg19)	Gene	Allele	Allele	Freq.	fat (SD)	(SD)	P value	Allele	Allele	Freq.	fat (SD)	(SD)	P value	Allele	fat (SD)	(SD)	P value	fat (SD)	(SD)	P value
Newly-identit	fied va	ariants																				
rs2642438	1	220970028	MARC1	G	Α	0.70	0.052	0.008	1.70E-09	G	А	0.71	0.088	0.028	1.60E-03	G	0.062	0.026	0.017	0.074	0.019	1.04E-04
rs1229984	4	100239319	ADH1B	С	Т	0.98	0.158	0.025	7.00E-10	С	Т	0.95	0.101	0.057	0.081	С	0.034	0.040	0.394	0.056	0.033	0.088
rs112875651	8	126506694	TRIB1	G	Α	0.61	0.050	0.008	3.80E-10	G	А	0.60	0.070	0.026	7.70E-03	G	0.044	0.023	0.059	0.055	0.017	1.40E-03
rs2250802	10	113921354	GPAM	G	Α	0.27	0.054	0.009	1.40E-09	G	А	0.30	0.058	0.028	0.037	G	0.031	0.025	0.218	0.043	0.019	0.021
rs56252442	19	18229208	MAST3	Т	G	0.25	0.049	0.009	2.70E-08	Т	G	0.19	0.065	0.032	0.041	Т	0.017	0.026	0.501	0.036	0.020	0.070
Previously-id	dentifi	ed variants																				
rs429358	19	45411941	APOE	Т	С	0.85	0.121	0.011	1.50E-29	Т	С	0.97	-0.119	0.075	0.110	Т	0.056	0.029	0.054	0.033	0.027	0.219
rs58542926	19	19379549	TM6SF2	Т	С	0.07	0.289	0.015	2.80E-85	Т	С	0.05	0.326	0.056	6.20E-09	Т	0.229	0.045	3.36E-07	0.267	0.035	2.25E-14
rs738408	22	44324730	PNPLA3	Т	С	0.21	0.195	0.009	5.30E-95	Т	С	0.24	0.278	0.030	2.50E-20	Т	0.294	0.024	1.35E-33	0.288	0.019	9.60E-53

Liver fat was measured by magnetic resonance imaging (MRI) in UK Biobank and by computed tomography (CT) imaging in the Framingham Heart Study (n=3284) and Multi-Ethnic Study of Atherosclerosis (MESA, n=4195). Effects of Framingham and MESA were combined via fixed-effects inverse variance weighted meta-analysis. Chr., chromosome; Freq., frequency; SD, standard deviation; SE, standard error.

	-						-								
Lead Variant	Chr.	Position (hg19)	Nearest Gene	Effect Allele	Other Allele	Effect Allele Freq.	Effect on liver fat (SD)	SE (SD)	P value	Effect on ALT (U/L)	SE (U/L)	P value	Effect on AST (U/L)	SE (U/L)	P value
Newly-Identif	ied Va	riants													
rs2642438	1	220970028	MARC1	G	А	0.70	0.052	0.008	2E-09	0.47	0.036	1E-39	0.16	0.028	5E-09
rs1229984	4	100239319	ADH1B	С	Т	0.98	0.158	0.025	7E-10	0.41	0.112	2E-04	0.32	0.086	2E-04
rs112875651	8	126506694	TRIB1	G	А	0.61	0.050	0.008	4E-10	0.56	0.034	2E-61	0.19	0.026	2E-13
rs2250802	10	113921354	GPAM	G	А	0.27	0.054	0.009	1E-09	0.41	0.037	3E-29	0.16	0.028	3E-08
rs56252442	19	18229208	MAST3	Т	G	0.25	0.049	0.009	3E-08	0.29	0.038	1E-14	0.03	0.029	0.342
Previously-R	eporte	ed Variants													
rs58542926	19	19379549	TM6SF2	Т	С	0.07	0.289	0.015	3E-85	1.28	0.062	2E-94	0.67	0.048	2E-44
rs429358	19	45411941	APOE	Т	С	0.85	0.121	0.011	2E-29	0.66	0.045	7E-49	0.07	0.035	0.045
rs738408	22	44324730	PNPLA3	Т	С	0.21	0.195	0.009	5E-95	1.68	0.040	<1E-300	1.06	0.031	8E-262

Supplementary Table 6. Effects of 8 common loci associated with quantitative liver fat on blood biomakers of liver injury.

Effects on alanine aminotransferase (ALT, n=345,930 with ALT measurement) and aspartate aminotransferase (AST, n=344,799 with AST measurement) were measured in the n=362,910 subset of the UK Biobank who did not undergo abdominal imaging. Chr., chromosome; Freq., frequency; SD, standard deviation; SE, standard error.

Supplementary Table 7. Effects of 8 common loci associated with quantitative liver fat on clinical diagnoses of liver disease.

										Mass General Brigham				obank +	
										Mass G		0		General E	•
							-	K Biobar	ık		Biobank		Biobank		
							Effect on			Effect on			Effect on		
							NAFLD/			NAFLD/			NAFLD/		
						Effect	NASH			NASH			NASH		
		Position	Nearest	Effect	Other	Allele	diagnosis	SE		diagnosis	SE		diagnosis	SE	
Lead Variant	Chr.	(hg19)	Gene	Allele	Allele	Freq.	(OR)	(logOR)	P value	(OR)	(logOR)	P value	(OR)	(logOR)	P value
Newly-identified variants															
rs2642438	1	220970028	MARC1	G	А	0.70	1.14	0.034	1.75E-04	1.06	0.027	0.03	1.09	0.021	4.44E-05
rs1229984	4	100239319	ADH1B	С	Т	0.98	1.33	0.118	0.015	1.26	0.052	6.69E-06	1.28	0.048	3.36E-07
rs112875651	8	126506694	TRIB1	G	А	0.61	1.10	0.032	1.71E-03	1.07	0.025	6.44E-03	1.08	0.020	4.35E-05
rs2250802	10	113921354	GPAM	G	А	0.27	1.08	0.033	0.016	1.07	0.026	7.51E-03	1.08	0.021	3.24E-04
rs56252442	19	18229208	MAST3	Т	G	0.25	1.00	0.035	0.991	1.04	0.028	0.20	1.02	0.022	0.32
Previously-ic	lentifi	ed variants													
rs429358	19	45411941	APOE	Т	С	0.85	1.24	0.045	1.39E-06	1.18	0.036	5.24E-06	1.20	0.028	4.83E-11
rs58542926	19	19379549	TM6SF2	Т	С	0.07	1.41	0.050	5.86E-12	1.38	0.044	7.76E-13	1.39	0.033	3.13E-23
rs738408	22	44324730	PNPLA3	Т	С	0.21	1.52	0.033	6.00E-37	1.38	0.027	8.52E-32	1.43	0.021	9.80E-66

Effects on NAFLD/NASH in a subset of the UK Biobank who did not undergo abdominal imaging (2,225 cases vs 360,685 controls) and NAFLD/NASH in Mass General Brigham Biobank (4,129 cases vs 26,444 controls) were measured. Effects of UK Biobank and Mass General Brigham Biobank were combined via fixed-effects inverse variance weighted meta-analysis. Chr., chromosome; Freq., frequency; OR, odds ratio; SE, standard error.

Supplementary Table 8. Rare inactivating variants in *APOB* are associated with decreased circulating lipids but increased markers of liver injury.

		APOB inactivating variant			<i>MTTP</i> inactivating variant	
	Controls (N=42196)	carriers (N=64) ^a	Adjusted P	Controls (N=42214) ^b	carriers (N=46) ^c	Adjusted P
Apolipoprotein B, mean (SD), g/L	1.03 (0.235)	0.619 (0.283)	1.77E-29	1.03 (0.236)	1.05 (0.212)	0.66
LDL cholesterol, mean (SD), mg/dL	146 (32.8)	81.2 (37.1)	4.48E-56	146 (32.9)	154 (33.8)	0.13
Triglycerides, mean (SD), mg/dL	157 (93.6)	94.5 (75.6)	8.86E-08	157 (93.6)	161 (59.6)	0.91
Alanine aminotransferase, mean (SD), U/L	23.5 (13.5)	30.7 (18.1)	1.73E-05	23.5 (13.5)	27.7 (17.4)	0.05
Aspartate aminotransferase, mean (SD), U/L	26.3 (10.3)	29.9 (12.5)	6.45E-03	26.3 (10.3)	28.4 (11.2)	0.21
Coronary artery disease, N (%)	2727 (6.5%)	1 (1.6%)	0.15	2726 (6.5%)	2 (4.3%)	0.45

^aApolipoprotein B values were missing in 25/64 inactivating variant carriers (39%), all other measurements had <=6% missing in either group.

 $^{\rm b}\mbox{Measurements}$ were missing in 6.2-6.5% of controls.

 $^{\rm c}\text{Measurements}$ were missing in 4/46 inactivating variant carriers (8.7%).